Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Small Cell Lung Carcinoma 18Lymphoma, Large B-Cell, Diffuse 16Leukemia, Myeloid, Acute 16Hodgkin Disease 16Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lung Neoplasms 12Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Lymphoma, B-Cell 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 6Recurrence 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Congenital Abnormalities 4Waldenstrom Macroglobulinemia 3Plasmablastic Lymphoma 3Ovarian Neoplasms 3Lymphoma, Primary Effusion 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

Vincristine 3Rituximab 3Prednisone 3Etoposide 3Doxorubicin 3Cyclophosphamide 3prednylidene 1pomalidomide 1liposomal doxorubicin 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Lenalidomide 1Endoscopy 1Electrocardiography 1Echocardiography 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Primary Effusion × Etoposide × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡